

BEST OF ASCO[®]

OFFICIALLY LICENSED

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
BENGALURU, INDIA 2025

Theme:

**Driving Knowledge to Action:
Building a Better Future**

PROGRAM SCHEDULE

23-24 August, 2025

Sheraton Brigade Gateway, Bengaluru

Endorsed by



Academia of Head & Neck
Oncology of Karnataka


Hosted by



GHA
GLOBAL HEALTHCARE
ACADEMY

SHERATON GRAND BRIGADE GATEWAY, BANGALORE

23-24 AUGUST, 2025



■ **GBR 1 & 2** (Grand Ball Room)

■ **JUPITER**
HALL - 4 (A & B)

■ **NEPTUNE**
HALL - 5

■ **PLUTO**
HALL - 6

■ **BOARD ROOM**
HALL - 7

DAY 1



23 August 2025 (Saturday)



08:00 – 17:00

SESSION HIGHLIGHTS

Time in Hrs (IST)	Track Code	Topics and Session Tracks
08:00 - 10:00	Pre Conference Workshop - 1	Postgraduate Exam Bootcamp: Skills, Strategy & Success MO - Hall - 4B SO - Hall - 7 RO - Hall-6

GRAND BALL ROOM

10:00 - 11:40	Scientific Session	Track: Metastatic Breast Cancer
14:20 - 15:40	Scientific Session	Track: Local - Locally Advanced Breast Cancer
16:30 - 18:15	Scientific Session	Track: Head & Neck Cancers
19:00 - 20:30	HCG	Dinner Symposium

JUPITER (HALL - 4A)

08:30 - 12:30	Focus Session 1	Palliative Oncology
14:00 - 17:00	Scientific Session	Track: Hematologic Malignancies

JUPITER (HALL - 4B)

10:00 - 12:30	Focus Session 2	Speech & Swallow
13:30 - 17:40	Focus Session 3	Onco Pharma; Genomics & Precision Oncology

NEPTUNE (HALL - 5)

08:30 - 17:30	Focus Session 4	Onco-Pathology
---------------	-----------------	----------------

PLUTO (HALL - 6)

10:00 - 11:20	BoA Award Paper	Award Paper Presentation - Best of ASCO, Bengaluru
---------------	-----------------	--

BOARD ROOM (HALL - 7)

14:00 - 17:30	Focus Track	Radiation Oncology
---------------	-------------	--------------------

BENE (LEVEL - 4)

18:00 - 19:00	ASCO Poster	Award Poster Presentation - Best of ASCO, Bengaluru
---------------	-------------	---

PRE CONFERENCE WORKSHOP HALL 4B		
08:00 - 10:00	PCWS 120 MINS	Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology Examiners: Dr. Krishna Kumar Ratnam (MO), Dr. Suresh Babu (MO)
PRE CONFERENCE WORKSHOP HALL 7		
08:00 - 10:00	PCWS 120 MINS	Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology Examiners: Prof. Chandramohan K (SO), Dr. Rakesh Ramesh (SO)
PRE CONFERENCE WORKSHOP HALL - 6		
08:00 - 10:00	PCWS 120 MINS	Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology Examiners: Prof. Nirmala S (RO), Dr. Siddanna (RO)
GRAND BALL ROOM		
Session 01 Track: Metastatic Breast Cancer		
Chairperson: Dr. Shekar Patil (MO)		
10:00 - 10:20	20 MINS	Welcome Address
10:20 - 10:40	INDUSTRY 20 MINS	Industry Session by Astra Zeneca: Topic: Endocrine resistance in HR+ve mBC in era of precision medicine Dr. Srinivas K G (MO)
10:40 - 10:55	INVITED 15 MINS	Invited Talk: Topic: Are we there yet? Molecular monitoring in HR Positive mBC Dr. Niti Raizada (MO)
10:55 - 11:15	MBC (06 MINS)	1013 Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor positive (HR+) metastatic breast cancer (mBC) in DESTINYBreast06 (DB-06). Dr. Prashanth Kumar Parida (MO)
	MBC (06 MINS)	LBA1008 Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09. Dr. Akansha Choudhary (MO)
	MBC (06 MINS)	LBA109 Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. Dr. Bhavesh Poladia (MO)

Moderators: Dr. Jyoti Bajpai (MO)

11:15 - 11:35	PANEL (20 MINS)	Panel Discussion: Breast Cancer - Metastatic Dr. Nishita Shetty (MO), Dr. Prashant Kumar Parida (MO), Dr. Vishwajit Pai (MO) Dr. Sarah Easaw (MO), Dr. Nidhi Tandon (MO)
11:35 - 11:50	INVITED (20 MINS)	Invited Talk: Topic: Topic Metastatic triple negative breast cancer beyond chemotherapy Dr. Biswajeet Dubashi (MO)
11:50 - 12:10	INDUSTRY (20 MINS)	Industry Session by Astra Zeneca: Topic: ENHERTU® for the treatment of HR+ HER2-low or HR+ HER2 ultra-low mBC Dr. Vishwanath Sathyanarayanan (MO)
12:10 - 12:30	INDUSTRY (20 MINS)	Industry Session by MSD: Topic: Redefining Treatment Outcomes with Immunotherapy - Early Triple Negative Breast Cancer (TNBC) Dr. Niti Raizada (MO)
12:30 - 13:00	KEYNOTE (30 MINS)	Keynote Talk: Topic: Harnessing the potential of modern participle beam therapy in immunomodulation and precision medicine to improve cancer survivals and survivorship Dr. Rakesh Jalali (RO)
13:00 - 13:30	KEYNOTE (30 MINS)	Keynote Talk: Topic: The Enigma of cancer:"Chasing Data driven outcomes, not protocols" Dr. BS Ajaikumar (RO)
13:30 - 14:00	(30 MINS)	LUNCH
14:00 - 14:20	INDUSTRY 20 MINS	Industry Session by Novartis: Topic: Panel Discussion on Patient Management considerations in HR+ HER2- Early Breast Cancer Dr. Amit Rauthan (MO)

Session 02 | Track: Local - Locally Advanced Breast Cancer

Chairperson: Dr. Gopinath K S (SO)

14:20 - 14:30	INVITED 10 MINS	Invited Talk: Topic: Role of anti her2 treatment in locally advanced breast cancer Dr. Suresh Babu (MO)
14:30 - 14:45	INVITED 15 MINS	Invited Talk: Topic: State of play: Neoadjuvant systemic therapy in breast cancer Dr. Sachin Trivedi
14:45 - 15:20	LABC (07 MINS)	LBA509 NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. Dr. Vinu Sarathy (MO)
	LABC (07 MINS)	501 Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. Dr. Spoorthi (MO)

	LABC (07 MINS)	504	Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. Dr. Aditya Sarin (MO)
	LABC (07 MINS)	505	15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS. Dr. Kiran P K (MO)
	LABC (07 MINS)	521	The effect of endocrine therapy omission on survival in ER-negative PR-low (1-10%) early-stage breast cancer treated with chemotherapy. Dr. Santhosh Kumar KN (MO)

Moderators: Dr. Anitha Ramesh (MO)

15:20 - 15:40	PANEL (20 MINS)	Panel Discussion: Local - Locally Advanced Breast Cancer Dr. Krithika Murugan (SO) , Dr. Bhavya Bayana (SO) , Dr. Janaki MG (RO) , Dr. Kakoli Lahkar (MO) , Dr. Harish P (MO) , Dr. Rachan Shetty (MO) , Dr. Ravi Chander Veligeti (SO) , Dr. Sourabh Radhakrishnan (MO)
15:40 - 16:00	INDUSTRY (20 MINS)	Industry Session by Lilly: Topic: Do all node positive HR+ Her2+ early breast cancer patients have same risk of recurrence? Dr. Sai Vivek (MO)
16:00 - 16:20	INDUSTRY (20 MINS)	Industry Session by Roche: Topic: Continuum of care in Her2 positive breast cancer Chairperson: Dr Govind Babu (MO) Moderator: Dr Avinash C B (MO) Panelists: Dr. Kiran PK (MO) , Dr. Niti Raizada (MO) , Dr. Satheesh CT (MO) , Dr Sai Vivek (MO) , Dr. Nidhi Tondon (MO) , Dr. Vijai Simha (MO)

16:20 - 16:25	(05 MINS)	TEA BREAK
---------------	-----------	------------------

Session 03 | Track: Head & Neck Cancers

Chairperson: Dr. Purushottam Chawan (SO), Dr. Ramesh Bilimadge (RO)

16:25 - 16:40	INVITED 15 MINS	Invited Talk: Topic: Indian T4b Buccal Cancers. Realigning staging and management Dr. Kaustubh Patel (SO)
16:40 - 17:15	HN (07 MINS)	LAB2 NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Dr. Vijai Simha (MO)
	HN (07 MINS)	2509 Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELI: Development of Low dose Immunotherapy in India). Dr. Sandip Ganguly (MO)
	HN (07 MINS)	6001 Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). Dr. Prathyush (MO)

	HN (07 MINS)	6008	Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFM-ATC): A multicenter phase 2 trial. Dr. Srigopal Mohanty (MO)
	HN (07 MINS)	6012	Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. Dr. Sneha Komineni (MO)

Chairperson: Dr. Dipak Haldipur (SO)

17:15 - 17:45	KEYNOTE (30 MINS)	Keynote Talk: Topic: Role of Immuno fluorescence in Surgical Oncology Dr. Raj Nagarkar (SO)
---------------	----------------------	--

Moderators: Dr. Neelesh Reddy (MO)

17:45 - 18:05	PANEL (20 MINS)	Panel Discussion: Head & Neck Cancers Dr. Kinjal S Majumdar (SO) , Dr. Sapna Nangia (RO) , Dr. Prashant Nayak (RO) Dr. Sreevalli Anantharamu (MO) , Dr. Prasad Eswaran (MO) , Dr. Vivek Agarwala (MO) Dr. Chandrashekhar Prasad Singh (MO) , Dr. Vaishnavi Joshi (MO)
18:05 - 18:25	INDUSTRY (20 MINS)	Industry Session by MSD: Topic: Head and Neck Cancer awareness and role of Keytruda in treatment of M/uR HNSCC Patients Dr. Sanchayan Mandal (MO)
18:25 - 18:45	INDUSTRY (20 MINS)	Industry Session by Astra Zeneca: Topic: Paradigm shift in the management of HER2 positive solid tumours Dr. Aditya Murali (MO)

18:45 - 19:00 (15 MINS) NETWORK BREAK

Dinner Symposium | HealthCare Global Enterprises

Chairperson: Dr. Ramesh Nimmagadda (RO)

19:00 - 19:15	INVITED (15 MINS)	AI in oncology : The Future is here Ms. Shobha Vijayaraghavan, Accenture Panelists: Mr. Ravi Bharadhwaj
19:15 - 19:45	KEYNOTE (30 MINS)	Keynote Talk: Topic: Decoding the enigma of Cancer: A Multidisciplinary approach to precision oncology for better Patient outcomes Dr. BS Ajaikumar
19:45 - 20:30	PANEL (45 MINS)	Panel Presentation / Discussions / Q & A Dr. Mithua Ghosh (Gen) , Dr. Shantanu Chowdhury (Gen) , Dr. Rahul Ramekar (Gen) Dr. Veena Ramaswamy (Path) , Dr. Kumaraswamy (RO) , Dr. Priyank Tripathi (CP) Dr. Abhishek Mohanty (Biorep) , Dr. Shalini Thakur (SO)

Hall - 4 A

Session 04 | Track: Hematological Malignancies

Chairperson: Dr. Krishna Kumar Ratnam

13:30 - 14:00	INVITED 30 MINS	Invited Talk: Topic: Establishing Industry collaboration with CAR-T Dr. Sharad Damodar	
14:00 - 14:20	INVITED 20 MINS	Invited Talk: Topic: Relapsed Myeloma: Sequencing of Therapies Dr. Mallikarjun Kalashetty	
14:20 - 14:40	INVITED 20 MINS	Invited Talk: Topic: Management of AML in the era of Targeted therapies Dr. Mahesh Rajashekhariah	
14:40 - 15:00	INVITED 20 MINS	Invited Talk: Topic: Hematopathology Dr. Jayashree	
15:00 - 15:45	HM (07 MINS)	LBA3	Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Dr. Vikram Mathew
	HM (07 MINS)	6504	An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. Dr. Megala
	HM (07 MINS)	7000	Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial. Dr. Amreesh Sukumaran
	HM (07 MINS)	7011	SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Dr. Santhosh H S
	HM (07 MINS)	7015	Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO Dr. Chaitanya Harita
	HM (07 MINS)	7507	Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). Dr. P K Jayachandran
15:45 - 16:15	INDUSTRY (30 MINS)	Industry Session by ImmunoAct: Topic: The Role of NexCAR19 CAR T Cell Therapy in B-Cell Malignancies: From India to the World Dr. Vishwanath Sathyanarayanan (MO)	
16:15 - 16:45	INDUSTRY (30 MINS)	Industry Session by Takeda: Topic: Case based panel discussion in Hodgkin's Lymphoma Moderator: Dr. Amit Rauthan Panelists: Dr. Arun Warrior, Dr. Mangesh Kamath, Dr. K.G. Srinivas, Dr. Smitha Saldanha, Dr. Rajeev Vijay Kumar	
16:45 - 17:05	INDUSTRY (20 MINS)	Industry Session by Bard / BD: Topic: Revolutionising PICC placement: What lies in the future Dr. Hari Menon (MO)	
17:05 - 17:25	INDUSTRY (20 MINS)	Industry Session by Pfizer: Topic: Redefining the First-Line Management of ALK Rearranged NSCLC Dr. Prasad Narayanan (MO)	

Moderators: Dr. Ashish Dixit

17:25 - 17:55	PANEL (30 MINS)	Panel Discussion: Hematological Malignancies Dr. Revanth Boddu, Dr. Neema Bhat, Dr. Hari Menon, Dr. Mangesh Kamath Dr. S K Gupta, Dr. P K Jayachandran, Dr. Vimal Kumar G
---------------	--------------------	--

Hall - 7

Session 5 | Track: Radiation Oncology Focus Track

Chairperson: Dr. Lokesh Vishwanath (RO), Dr. Vijay Bhaskar (RO)

14:00 - 14:20	INVITED 20 MINS	Invited Talk: Topic: Flash Radiotherapy: Is there light at the end of the tunnel Mr. Jerin (Physics)
14:20 - 14:40	INVITED 20 MINS	Invited Talk: Topic: De escalation of Adjuvant RT in breast cancer - recent evidences Dr. Nirmala S (RO)

14:40 - 15:10	RO (07 MINS)	LBA5504	Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Dr. Priya Sinha (SRO)
	RO (07 MINS)	LBA6003	PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial. Dr. Abhijit Sarkar (RO)
	RO (07 MINS)	6013	Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). Dr. Sunil (RO)
	RO (07 MINS)	LBA4005	PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). Dr. Sindhu KR (RO)

Moderator: Dr. Geeta S Narayanan (RO)

15:10 - 15:40	PANEL (30 MINS)	Panel Discussion: Lung & Thoracic Cancers Dr. Vinay Ural (RO), Dr. Mohan (RO), Dr. Kirthi Koushik (RO), Dr. Afthab Ansari (RO), Dr. Vinaykumar Muttagi (RO), Dr. Tanvir Pasha (RO), Dr. Deepanjali Patel (RO), Dr Vijay Agarwal (MO)
---------------	--------------------	--

Chairperson: Dr Kumaraswamy (RO), Dr MS Belliappa (RO)

15:40 - 16:00	INVITED 20 MINS	Invited Talk: Topic: Proton Therapy for Head Neck Cancer: Evidence & Experience. Dr. Sapna Nagia (RO)
16:00 - 16:20	INVITED 20 MINS	Invited Talk: Topic: AI in Radiation Oncology Dr. Balakrishna Nair (RO)

16:20 - 16:50	RO (07 MINS)	2011	Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial Dr. Gayathri Patil (RO)
	RO (07 MINS)	5511	Priamry Results of a phase 2 study of cisplatin sensitized radiation therapy Dr. Taher Manaquibwala (RO)
	RO (07 MINS)	TPS4620	A randomized phase 2 study of the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with metastatic urothelial carcinoma and oligoprogression on maintenance therapy with avelumab (VOLGA 2). Dr. Shreya Koundinya (RO)
	RO (07 MINS)	LBA12000	PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer. Dr. Adarsh Gajanan Hegde (RO)

Moderator: Dr. Sourabha Shetty (RO)

16:50 - 17:20	PANEL (30 MINS)	Panel Discussion: Dr. Milind Shetti (RO) , Dr. Mathangi Padmanabhan (RO) , Dr. Vikram Maiya (RO) , Dr. Vijay Karan Reddy (RO) , Dr. Karthik Hrishi (RO) , Dr. Janaki MG (RO) Dr. Lohith Reddy (RO) , Dr. Srinivas BJ (MO)
---------------	--------------------	---

Moderator: Dr. Sourabha Shetty (RO)

17:30 - 18:00	KEYNOTE (30 MINS)	Keynote Session: Topic: "Cut Less, Cut More": Tailoring Surgery to Response Dr. Anil D'Cruz
---------------	----------------------	--

Parallel Tracks

Focus Session 1 | Palliative Oncology | Hall 4A

Time in Hrs (IST)	Keynote Session	Topic
08:30 - 09:00	Dr. Anuja Pandit	Digital Health and AI in Palliative Decision Support
09:00 - 09:30	Dr. Nandini Vallath	Beyond Pain: Defining, Measuring, and Managing the Multidimensional Landscape of Serious Health-Related Suffering
09:30 - 10:00	Ms. Smriti Rana	Rewriting the Narrative: Dignity, Identity, and Meaning in Cancer Care
10:00 - 10:15	Tea Break	
	Panel Discussion	Topic
10:15 - 11:25	Moderator: Dr. Praneeth Suvvari Panelist: Dr. Vijay Agarwal, Dr. Amelia Michael, Prof. (Dr.) S.V. Joga Rao, Ms. Michelle Normen	“They Want Everything Done” Navigating Demanding Families and Futile Interventions

Time in Hrs (IST)	Keynote Session	Topic
11:25 - 11:55	Dr. Raghavendra Ramanjulu	Patient-Reported Outcomes (PROs): From Clinical Trials to Clinical Care.
11:55 - 12:25	Dr. Veereswara Raju SK	De-escalation of Cancer Therapy: A Palliative Opportunity

Focus Session 3 | Clinical Pharmacogenomics & Precision Oncology | Hall 4B

Time in Hrs (IST)	Topics	Speaker
13:30 - 13:45	Introductory address and workshop overview	Dr. Mithua Ghosh (Gen), Dr. Jyoti Bajpai (MO)
13:45 - 14:05	NGS Fundamental: Basics of NGS. What, Why and How?	Dr. Rahul Ramekar (Gen)
14:05 - 14:25	Data analyses: Overview of Tools and Databases; Data analysis workflow	Dr. Anuja Mishra
14:25 - 14:45	Overview of variant prioritization and interpretation in solid tumors	Dr Soundararajan Nagaraj
14:45 - 15:05	Precision Oncology: Where are we?	Dr. Om Shree Shetty (Gen)
15:05 - 15:25	Industry Session by MGI Tech Co. Ltd: Topic: Enrichment Methods for Precision Oncology: NGS-based Hybrid Capture of CGP & Medium Pan-Cancer Amplicon Panels for Oncology ROI	Dr. Ravi Kumar Chilukoti
15:25 - 15:30	Tea Break	
15:30 - 15:55	Pharmacogenomics & Drug Targeting: Basics of Pharmacogenomics and its role in precision medicine: From Bench to bedside.	Dr. Priyank Tripathi (CP)
15:55 - 16:15	Pharmacogenomics: Future Perspective: Pharmacogenomics shaping drug development	Dr. Haritha P V (CP)
16:15 - 16:35	Industry Session by Johnson & Johnson: Topic: A Breakthrough in NSCLC: The promise of Amivantamab for EGFR Exon 20 insertions	Dr. Vishwajit Pai (MO)
16:35 - 16:55	Power of Genomic Medicine: Breast Cancer Genomics to India-specific Clinical Panels	Dr. Shantanu Chowdhury (Gen)
16:55 - 17:15	Moderator: Dr Mithua Ghosh Topic: Case Studies in Precision Medicine. Patient case Discussion; genomic-guided oncology treatment	Panelists: Dr. Vijay Aggarwal (MO), Dr. Srinivas BJ (MO) Dr. Jyoti Bajpai (MO), Dr. Amit Dutt (MO) Dr. Chandru J (Gen), Dr. Gautam Balram (Gen) Dr. Birendranath Banerjee (Gen), Dr. Soundararajan Nagaraj
17:15 - 17:30	Future Frontiers in Oncology: Advancing cancer care through integration of genomics, therapeutics, and innovation	Dr. BS Ajaikumar (RO)
17:30 - 17:35	Closing Remarks & Launch of the new educational program	Dr. Priyank Tripathi (CP), Dr. Rahul Ramekar (Gen)

Focus Session 4 | Onco Pathology | Hall 5

08:30 - 09:15	Registration	
09:15 - 09:20	Inauguration	
09:20 - 09:25	Context Setting - Dr. Veena Ramaswamy	
SESSION - 01 BREAST BIOMARKERS		
Time in Hrs (IST)	Session	Speaker
09:25 - 09:50	Breast Biomarkers	Dr. Swarna Shivkumar
09:50 - 10:05	Latest Update in Her-2 interpretation	Dr. Manjit Kaur
10:05 - 10:25	Hands on Interpretation	
10:25 - 10:45	Discussion	Moderated by: Dr. Shaila B
10:45 - 10:55	Tea Break	
SESSION - 02 IMMUNE CHECK POINT INHIBITORS		
10:55 - 11:15	Interpretation and application of PDL1	Dr. Shilpa Prabhudesai
11:15 - 11:35	Hands on Interpretation	
11:35 - 11:50	Discussion	Moderated by: Dr. Shilpa Prabhudesai
11:50 - 12:10	Industry Session by BMS: Topic: NSCLC topic: Breaking frontiers in 1L mNSCLC Leveraging Anti PD-1 & Anti CTLA-4 forhigh unmet need patients Dr. Mangesh Kamath (MO)	
12:30 - 13:30	Keynote Address - Grand Ball Room	
13:10 - 13:40	Lunch Break	
13:40 - 14:00	Industry Session by NATCO: Topic: Role of TUCATINIB in HER 2 positive MBC Dr. Sai Vivek (MO)	
SESSION - 03 SURROGATE MARKERS OF IMMUNOTHERAPY		
14:00 - 14:15	MMR / MSI	Dr. Champaka
14:15 - 14:30	TMB	Dr. Gautam Balaram
14:30 - 14:45	Hands on Interpretation	
14:45 - 15:00	Discussion	Moderated by: Dr. Champaka & Dr. Gautham B
SESSION - 04 LUNG BIOMARKERS		
15:00 - 15:10	Interpretation and Application of Lung Biomarkers	Dr. Tejaswini BN
15:10 - 15:25	Hands on Interpretation	
15:25 - 15:40	Discussion	Moderated by: Dr. Tejaswini BN
15:40 - 16:00	Industry Session by Roche(Diagnostics): Biomarkers in early NSCLC - Focus on ALK Dr. Veena Ramaswamy	
16:00 - 16:10	Tea Break	
SESSION - 05 OTHER TARGETED BIOMARKERS		
16:10 - 16:30	Other Targeted Biomarkers	Dr. Manjubala
16:30 - 16:50	Hands on Interpretation	
16:50 - 17:05	Discussion	Moderated by: Dr. Manjubala
17:05 - 17:15	Active Interaction and Discussion	Dr. Kavita B
17:15 - 17:20	Vote of Thanks	

Award Paper Session | Hall 6

10:00 - 10:07	Residual cancer burden index (RCBI) after neoadjuvant therapy - an independent prognostic marker in carcinoma breast.	Dr. Garapati Divyajyothi
10:07 - 10:14	Survival outcome in node positive oral tongue cancer patients	Dr. Akhil P
10:14 - 10:21	Feasibility and clinical outcomes of the infrahyoid flap in reconstruction of small to medium-sized defects in oral cavity cancers	Dr. Sowmya T
10:21 - 10:28	Her2 expression detected by next-generation sequencing in a her2-negative males with secretory breast cancer: a precision-based diagnostic approach in a rare pediatric case	Dr. Somrita Das
10:28 - 10:35	To study the utility of Traffic Light Protocol (TLP) in head and neck VMAT	Dr. Rajalakshmi Radhakrishnan
10:35 - 10:42	Real-world treatment outcomes in malignant ovarian germ cell tumors: a single-center perspective	Dr. Snigdha Das
10:42 - 10:49	Surgical modalities of oral submucous fibrosis review of literature and a case view	Dr. Aniket Chauhan
10:49 - 10:56	Therapeutic outcomes of neo adjuvant immunotherapy in advanced hepatocellular carcinoma: a promising approach for curative intent	Dr. Manoj Kumar YL
10:56 - 11:03	Robotic vs laparoscopic adrenalectomy for pheochromocytoma - is there any difference? - a comparative study from a tertiary care cancer center.	Dr. Anirudh M
11:03 - 11:10	Immune-check point inhibitors related myocarditis: diagnostic dilemmas and emerging therapies	Dr. Maazen Naduthra Subair

Award Poster Session | Bene | Level 4

16:15 - 17:15	Award Poster Session	Jury Dr. Suresh Babu (MO) TBD TBD
---------------	-----------------------------	--

DAY 2



24 August 2025 (Sunday)



08:00 – 17:00

SESSION HIGHLIGHTS

Time in Hrs (IST)	Track Code	Topics and Session Tracks
-------------------	------------	---------------------------

GRAND BALL ROOM

10:40 - 11:40	Scientific Session	Tracks: HPB, CRC, Gastrointestinal, Cancers
11:45 - 13:20	Scientific Session	Track: Lung & Thoracic Cancers
13:10 - 16:20	Scientific Session	Track: Genitourinary Cancer
16:45 - 17:45	Scientific Session	Track: Gynecologic Cancer

JUPITER (HALL - 4)

08:30 - 17:00	Focus Session 6	Yoga
---------------	-----------------	------

NEPTUNE (HALL - 5)

09:00 - 17:00	Focus Session 7	Research Methodology
---------------	-----------------	----------------------

PLUTO (HALL - 6)

10:00 - 12:00	Focus Session 8	Nuclear Oncology
14:00 - 17:00	Scientific Session	Track: Pediatric Hematology Oncology

BOARD ROOM (HALL - 7)

10:00 - 13:30	Focus Track	Surgical Oncology
---------------	-------------	-------------------

GRAND BALL ROOM		
09:10 - 09:30	INDUSTRY 20 MINS	Industry Session by Takeda: Topic: ALT Strategies in the Management of ALK+NSCLC with ALUNBRIG Dr. Prasad Narayanan (MO)
Chairperson: Dr. Sai Ram Chintamadaka (RO)		
09:30 - 10:00	KEYNOTE (30 MINS)	Keynote Talk: Topic: Key advancements in management of advanced thyroid cancers - updates from ASCO 2025 Dr. Arvind Krishnamurthy (SO)
10:00 - 10:20	INDUSTRY 20 MINS	Industry Session by Bard / BD: Topic: Revolutionising PICC placement: What lies in the future Dr. Vivek Agarwala (MO)
10:20 - 10:40	INDUSTRY 20 MINS	Industry Session by Astra Zeneca: Topic: Newer paradigms in the management of Gastric cancers(Matterhorn) Dr. Amit Rauthan (MO)
Session 06 Track: HPB, CRC, Gastrointestinal, Cancers		
Chairperson: Dr. Poonam Patil (MO), Dr. Vijay Agarwal (MO)		
10:40 - 11:00	GI (05 MINS)	LBA1 Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). Dr. Sanchayana Mandal (MO)
	GI (05 MINS)	4000 Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. Dr. Abhinav Narwariya (MO)
	GI (05 MINS)	2511 Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis. Dr. Vijay Kumar Sreenivasalu (MO)
	GI (05 MINS)	LBA3500 First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses Dr. Srikant Ravichandran (MO)
Moderators: Dr. Vamsi Krishna (MO)		
11:00 - 11:20	PANEL (20 MINS)	Panel Discussion: HPB, CRC, Gastrointestinal, Cancers Dr. Anitha Ramesh (MO), Dr. Arun Warriar (MO), Dr. Rajeev L K (MO), Dr. Vishal Kulkarni (MO), Dr. Kumar Saurabh (MO)
11:20 - 11:25	(05 MINS)	TEA BREAK
11:25 - 11:45	INDUSTRY 20 MINS	Industry Session by Astra Zeneca: Topic: Transforming Patient Outcomes with Newer Innovative Therapies in 1L Advanced mHCC (STRIDE) Dr. Govind Babu (MO)

11:45 - 12:05	INDUSTRY 20 MINS	Industry Session by Roche: Topic: Management of uHCC - Defining TACE Unsuitability & Initiating Systemic Therapy Dr. Krishna Prasad (MO)
---------------	---------------------	---

Session 07 | Track: Lung & Thoracic Cancers

Chairperson: Dr. Ravi Diwakar (MO), Dr. MS Beliappa (RO)

12:05 - 12:20	INVITED 15 MINS	Invited Talk: Topic: Liquid Biopsies for monitoring Lung Cancers Dr. K Govind Babu (MO)
12:20 - 12:35	INVITED 15 MINS	Invited Talk: Dr. Krishna Prasad (MO)

12:35 - 13:00	LUNG (05 MINS)	8001	Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. Dr. Sandip Ganguly (MO)
	LUNG (05 MINS)	LBA8000	Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. Dr. Alok Modi (MO)
	LUNG (05 MINS)	8006	Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Dr. Aditya Mehta (MO)
	LUNG (05 MINS)	8503	Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab. Dr. Aadil Hassan (MO)
	LUNG (05 MINS)	8506	Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. Dr. Basawantrao Malipatil (MO)

Moderators: Dr. Ullas Batra (MO)

13:00 - 13:20	PANEL (20 MINS)	Panel Discussion: Lung & Thoracic Cancers Dr. Lohith Reddy (RO), Dr. Vaishnavi Joshi (MO), Dr. Mangesh Kamath (MO), Dr. Aditya Dhanawat (MO), Dr. Abhay Kumar SM (MO)
13:20 - 13:40	INDUSTRY 20 MINS	Industry Session by MSD: Topic: Novel Treatment Option in Lung Cancer with Focus on Pembrolizumab Dr. Vishwanath Sathyanarayanan (MO)

13:40 - 14:10	(30 MINS)	LUNCH BREAK
---------------	-----------	--------------------

14:10 - 14:30	INDUSTRY 20 MINS	Industry Session by Astra Zeneca: Topic: Reimagining EGFRm Advanced lung cancer Dr. Sai Vivek (MO)
---------------	---------------------	---

14:30 - 14:50	INDUSTRY 20 MINS	Industry Session by Glenmark: Topic: Tislelizumab in lung malignancies: Changing the course Dr. Amit Rauthan (MO)
---------------	---------------------	--

Session 08 | Track: Genitourinary Cancer

Chairperson: Dr. Somorat Bhattacharjee (RO), Dr. Veerendra Kumar KV (SO)

14:50 - 15:10	INDUSTRY 20 MINS	Industry Session by MSD: Topic: Shifting Paradigm in Metastatic Renal Cell Carcinoma with Immunotherapy Dr. C N Patil (MO)
---------------	---------------------	---

15:10 - 15:40	GU (05 MINS)	4500	Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. Dr. Abhinav Narwariya (MO)
	GU (05 MINS)	4505	Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. Dr. Abhilash G H (MO)
	GU (05 MINS)	4517	Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study. Dr. Aditya (MO)
	GU (05 MINS)	4514	Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). Dr. Anup Hegde (MO)
	GU (05 MINS)	5002	Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry. Dr. Venkata Koyyala (MO)
	GU (05 MINS)	4503	Circulating tumor DNA (ctDNA) in patients with muscle invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. Dr. Yogesh Shivakumar (Gen)

Moderators: Dr. Vinayak Makka (MO)

15:40 - 16:00	PANEL (20 MINS)	Panel Discussion: Genitourinary Cancer Dr. Ravichandran K (SO), Dr. Vijay Karan Reddy (RO), Dr. Anup Hegde (MO), Dr. Naveen Jayaram Anvekar (MO), Dr. Harish Reddy (MO), Dr. Sateesh CT (MO)
16:00 - 16:20	INDUSTRY (20 MINS)	Industry Session by Astra Zeneca: Topic: Paradigm shift in the management of advanced endometrial cancer Dr. Rohit Raghunath Ranade (GY)

16:20 - 16:25	(05 MINS)	TEA BREAK
---------------	-----------	------------------

Session 09 | Track: Gynecologic Cancer

Chairperson: Dr Linu Jacob (MO), Dr Radheshyam Naik (MO), Dr Haseeb Abdul Gafoor (RO)

16:25 - 16:50	GY (06 MINS)	5510	Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study. Dr. Muhammad Islam (MO)
	GY (06 MINS)	LBA5500	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Dr. Swathi Prakash (MO)
	GY (06 MINS)	LBA5507	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). Dr. Deepa (MO)
	GY (06 MINS)	5511	Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer. Dr. Darshana Rane (MO)

Moderators: Dr. C N Patil (MO)

16:50 - 17:10	PANEL (20 MINS)	Panel Discussion: Gynecologic Cancer Dr. Sunit Lokhwani (MO) , Dr. Kiran Kattimani (MO) , Dr. Indoo Ambulkar (MO) , Dr. Sampath Kumar M N (MO) , Dr. Subramaniam Murali (MO)
17:10 - 17:30	AWARDS 20 MINS	Award Papers & Poster - Award Distribution Dr. Suresh Babu (MO)

Hall - 6

Session 10 | Track: Pediatric Oncology

Chairperson: Dr. Appaji L, Dr. Raghuram P

13:30 - 14:00	INVITED 30 MINS	Invited Talk: Topic: Recent advances in the Management of Neuroblastoma Dr. Girish Chinnaswami
	PO (07 MINS)	1000 Association of immunotherapy of high-risk neuroblastoma patients with long term infusion of dinutuximab beta with survival over short term infusion: Results from the HR-NBL1/SIOPEN trial. Dr. Pooja Prakash Mallya
	PO (07 MINS)	10001 A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) report. Dr. Ravi Joshi

14:00 - 15:00	PO (07 MINS)	10005	Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. Dr. Shashank Bhojaraja
	PO (07 MINS)	10009	Promoting Resilience in Stress Management (PRISM): A randomized controlled trial of a psychosocial intervention for adolescents and young adults with advanced cancer. Dr. Rhea Daruvala
	PO (07 MINS)	10013	CCDI-COG molecular characterization initiative: The expanding data on childhood cancer. Dr. Gautam Balram
	PO (07 MINS)	10014	Genomic newborn screening for cancer risk: A retrospective cohort study. Dr. Somdipa Pal
	PO (07 MINS)	10016	Cognitive outcomes following proton vs. photon radiotherapy for CNS nongerminomatous germ cell tumors: A Children's Oncology Group study. Dr. Aarthi N
	PO (07 MINS)	10019	Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children's Oncology Group AHOD1331. Dr. Amit Galgali

15:00 - 15:20	INDUSTRY 20 MINS	Industry Session by BMS: Topic: RCC Topic - Improving Survival and Quality of Life in frontline advanced RCC with CTLA-4 & PD-1 inhibition : 8-year update. Dr. Rajeev Vijayakumar (MO)
---------------	---------------------	--

Moderators: Dr. Intezar Mehdi

15:20 - 15:50	PANEL (30 MINS)	Panel Discussion: Pediatric Oncology Dr. Shobha , Dr. Rasmi Thallessery , Dr. Smitha , Dr. Anand KC , Dr. Brindha Sitaram , Dr. Mithua Ghosh , Dr. Vinay MV
---------------	--------------------	--

Hall - 7

Session 11 | Track: Surgical Oncology Focus Track

Chairperson: Dr. Ravi Arjunan (SO), Dr Narendra H (SO), Dr. Nanda Rajneesh (SO)

10:15 - 10:45	INVITED 30 MINS	Invited Talk: Topic: Journey of a surgical oncologist - past, present and future Dr. Raj Nagarakar (SO)
---------------	--------------------	--

Chairperson: Dr. Deepak Rautray (SO), Dr. Shishir Shetty (SO)

Moderator: Dr. Jagannath Dixit (SO)

10:45 - 11:30	PANEL (45 MINS)	Panel Discussion: AI in Robotic surgery Dr. Mohan Krishnamurthy (SO) , Dr. Jayanti Thumsi (SO) , Dr. Lohit Reddy (RO) , Dr. Pawan Sugoor (SO) , Dr. Narasimhaiah Sreenivasiah (SO) , Dr. Sudhakar (Rad) , Dr. Yash Mathur (SO) , Dr. Srinivas Gopinath (SO)
---------------	--------------------	---

Chairperson: Dr. Mahesh Bandemagal (SO), Dr. Deepak Khanna (SO), Dr. Shivpal Saini (SO)

11:30 - 12:00

INVITED
30 MINS

Invited Talk:

Topic: Bridging the gap between the technology and the surgeon
[Mr. Devareddy \(HealthTech\)](#)

Chairperson: Dr. Sqn Ldr Swati Batra (SO), Dr. Ashwin KR (SO), Dr. Jyoti Ranjan Swain (SO)

12:00 - 12:25

GY
(05 MINS)

5583

Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advancedstage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.
[Dr. Vishnu Kurpad \(SO\)](#)

GY
(05 MINS)

LBA5501

Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial.
[Dr. Renu Sharma \(SO\)](#)

GY
(05 MINS)

4008

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
[Dr. Aditi Ranganath \(MO\)](#)

GY
(05 MINS)

3505

Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6)
[Dr. Kapil Dev \(SO\)](#)

GY
(05 MINS)

4007

Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.
[Dr. Aakarsh G Kini \(SO\)](#)

Chairperson: Dr. Rohan Shetty (SO), Dr. Prabhu Nesargikar (SO), Dr. Ravi Chander Veligeti (SO)

Moderator: Dr. Suraj Manjunath (SO)

12:25 - 13:05

PANEL
(40 MINS)

Panel Discussion: ASCO Update: What can we imbibe into India practice
[Dr. Sharanbasappa Hatti \(SO\)](#), [Dr. Rudresh Tabali \(SO\)](#), [Dr. Tanay Shah \(SO\)](#),
[Dr. Rohini Kulkarni \(SO\)](#), [Dr. Palaniappan Ramanathan \(SO\)](#), [Dr. Karthik Raichurkar \(SO\)](#), [Dr. Hemanth GN \(SO\)](#), [Dr. Vijaykumar M \(SO\)](#)

13:05 – 13:35

(30 MINS)

LUNCH BREAK

Focus Session 6 | Integrating Yoga into Cancer Care | Hall 4

Time in Hrs (IST)	Session Lead	Dr. Amritanshu Ram
08:45 - 08:50	Inauguration & Lighting the Lamp	
08:50 - 08:55	Prayer & Invocation	
	Session Chair: Dr. BS Ajaikumar	
08:55 - 09:25	Keynote Session: Topic: How Much Evidence is Enough: Yoga as the Standard of Care in Oncology Dr. Lorenzo Cohen	
09:30 - 10:00	Keynote Session: Topic: Key advancements in management of advanced thyroid cancers - updates from ASCO 2025 Dr. Arvind Krishnamurthy	
	Session Chair: Dr. Shekhar Patil	
10:10 - 10:30	Keynote Session: Topic: Evolving role of yoga as a scalable, evidence-based intervention in supportive cancer care MS. Leibel Leigh	
	Session Chair: Dr. R Nagaratna R, Dr. Vinoda Kochupillai	
10:40 - 10:50	Invited Talk: Topic: The journey from alternative to integrative medicine Dr. Nagaratna R	
10:50 - 11:00	Invited Talk: Topic: Holistic healing from an oncologists perspective Dr. Vinoda Kochupillai	
11:00 - 11:30	Invited Talk: Topic: Setting up integrative oncology at HCG Dr. KS Gopinath	
11:30 - 12:00	Invited Talk: Topic: How does Yoga as therapy work? Dr. Raghavendra Rao	
	Moderator: Dr. Raghavendra Rao	
12:00 - 13:00	Panel Discussion: Topic: How much Evidence is enough evidence? - Direction for future research in Yoga in Oncology Dr. KS Gopinath KS, Dr. Kritika Murugan, Dr. Brindha Sitaram, Dr. Zankhana Buch	
13:00 - 13:30	Project Launch: Topic: HCG: Elitefit remote yoga monitoring launch Mr. Ani Bhalekar, Dr. Amritanshu Ram	

13:30 - 14:00	Network & Lunch
	Session Chair - Dr. Kumaraswamy
14:00 - 14:20	Invited Talk: Topic: Role of yoga in modulating salivary cortisol rhythm in breast cancer patients undergoing radiation Dr. Vadiraja HS
14:20 - 14:40	Invited Talk: Topic: Integrating yoga in Cancer Care Dr. Anjali Joshi
14:40 - 15:00	Invited Talk: Topic: Effect of pranayama and yoganidra on QOL in cervical cancer patients Dr. Nuzhat Jahan
15:00 - 15:20	Invited Talk: Topic: Living with Cancer is more important than dying of cancer. An integrated approach Dr. Birendranath Banerjee
15:20 - 15:40	Invited Talk: Topic: Effects of integrated yoga therapy on cognition and cardiac functions in patients with breast carcinoma undergoing chemotherapy Dr. Inbaraj G
15:40 - 16:00	Invited Talk: Topic: Yoga for Cancer Survivorship Dr. Praseeda Menon
16:00 - 16:20	Invited Talk: Topic: Integrating yoga into cancer care. US experience in research and clinical practice Dr. Smitha Malliah
	Moderator: Dr. Amritanshu Ram
16:20 - 16:50	Panel Discussion: Topic: How to integrate yoga into Oncology Practice: Experiences, Challenges and opportunities Dr. Vadiraja HS, Dr. Smitha Malliah, Dr. Yamuna Badiger, Dr. Amruth Kadam, Dr. Shivaram Verambally

Focus Session 7 | Research Methodolgy | Hall 5

Time in Hrs (IST)	Topic	Speaker
09:00 - 09:15	Inaugural program	
09:15 - 09:45	What is Health Research? Why Research?	Dr. Nagesh Lakshminarayan
09:45 - 10:15	Procedural steps in Health Research	Dr. Nagesh Lakshminarayan
10:15 - 10:45	Framing a research Question- PO, PEO and PICO Format	Dr. Shyam Sivasamy
10:45 - 11:00	Tea Break	
11:00 - 11:45	Hypothesis Testing	Dr. Nagesh Lakshminarayan
11:45 - 12:30	Research Designs - Overview	Dr. Shyam Sivasamy
12:30 - 01:15	Errors in Health Research and Error minimization methods	Dr. Nagesh L
01:15 - 01:45	Lunch Break	
01:45 - 02:30	Fundamentals of Biostatistics (Data, Scales of measurements and implications)	Dr. Shyam Sivasamy
02:30 - 03:30	Measures of central tendency, Measures of Dispersion and Tests of Significance	Dr. Shyam Sivasamy
03:30 - 04:30	Scientific Writing – An Overview	Dr. Nagesh Lakshminarayan
04:30 - 04:50	Q and As	
04:50 - 05:00	Valedictory	

Focus Session 8 | Nuclear Oncology | Hall 6

Time in Hrs (IST)	Speaker	Session Title
10:00 - 10:30	Dr. Harish Babu	Basics & Applications of Nuclear Medicine in a Nutshell
10:30 - 11:00	Dr. Shiva Kumar Swamy	What You Have to Know About FDG PET/CT ?
11:00 - 11:20	Teak Break	
11:20 - 11:50	Dr. Mahesh A	Nuclear Medicine Imaging in Neuroendocrine Tumours (NET)
11:50 - 12:20	Dr. Kiran Kumar JK	Ga 68 PSMA and Other Radiotracers
12:20 - 12:50	Dr. Murthy S	Nuclear Medicine Therapy – Current Practices

Award Distribution | Grand Ball Room

17:45 - 18:05	Award Papers & Poster - Award Distribution	Dr. Suresh Babu (MO)
---------------	---	----------------------


BEST OF ASCO[®]

OFFICIALLY LICENSED

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

BENGALURU, INDIA 2025

Endorsed by



Academia of Head & Neck
Oncology of Karnataka

Hosted by



GHA
GLOBAL HEALTHCARE
ACADEMY

CONTACT US



Mr. George | +91 9008993636

Mr. Gautam Menon | +91 9731853344



ascoindia@globalhealthcareacademy.in



www.globalhealthcareacademy.in/bestofasco

